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A B S T R A C T
The delivery of drugs to the brain is complicated by the multiple factors including low blood brain barrier
(BBB) passive permeability, active BBB ef`ux systems, and plasma protein binding. Thus, a detailed under-
standing of the transport of the new potent substances through the membranes is vitally important and their
physico-chemical characteristics should be analyzed at _rst. This work presents an evaluation of drug likeness
of eight 7-O-arylpiperazinylcoumarin derivatives with high aanity towards serotoninergic receptors 5-HT⁠1A and
5-HT⁠2A with particular analysis of the requirements for the CNS chemotherapeutics. The binding constants to
human serum albumin (HSA) were determined at physiological pH using `uorescence spectroscopy, and then
their mode of action was explained by analysis of theoretical HSA complexes. Dynamic simulation of systems
allowed for reliable evaluation of the interaction strength. The analyzed coumarins were able to pass BBB, and
they present good drug likeness properties. They showed high aanities to HSA (log K⁠Q =5.3 6.0 which corre-
sponds to 8.12 to 7.15kcal/mol of Gibbs free energy). The changes of the emission intensity upon binding
to HSA were scrutinized showing the different mode of action for 4-phenylpiperazinylcoumarins. The values of
computed Gibbs free energy and determined on the basis of experimentally obtained binding constants log K⁠Q
coincide suggesting a good quality of the theoretical model. Overall the 8-acetyl-7-O-arylpiperazinyl-4-methyl-
coumarin derivatives represent valuable lead compounds to be further tested in various preclinical assays as a
possible chemotherapeutics against CNS diseases. Studied coumarins can be metabolized by cytochrome P450
to aldehydes and hydroxy derivatives. The existence of other binding sites inside HSA than Sudlow s site 1 was
postulated. The longer aliphatic linker between coumarin and piperazine moieties favored binding to HSA in
other than Sudlow site 1 pocket.
1. Introduction
The main challenge during the development of new medicinal sub-
stances which target the central nervous system (CNS) is to ensure
that the substance is present at the pharmacological target site at suf-
_cient concentration in order to demonstrate clinical ef_cacy [1]. Al-
though the strong binding of a drug molecule to its intended tar-
get is crucial for the strength of action, poor membrane perme
ability could result in a lack of in vivo ef_cacy. Thus, a detailed un-
derstanding of the transport of the substance through the membranes
is vitally important for pharmacokinetic analysis and for a successful
drug development. Drugs that specifically target the CNS must pass
three major central barriers: the blood brain barrier (BBB) formed by
capillary endothelial cells, the blood-cerebrospinal `uid barrier (CSFB)
formed by choroid plexus epithelia, and the third barrier formed by
tightly connected arachnoid epithelium. The absence of the intercel-
lular pores in the endothelial barrier in the brain means
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logarithm of the brain/blood partition coef_cient; MM-PBSA, molecular mechanics Poisson Boltzmann surface area; MRTD, maximum recommended therapeutic dose; MWt, molecular
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Fig. 1. The chemical structure of tested coumarin derivatives 1a 4a and 1b 4b.
that molecules gain access to brain interstitial `uid by the lipid-medi-
ated free diffusion or the carrier or receptor-mediated transport. The
BBB is the most important barrier in the brain [2], that separates the
brain from the rest of the body extracellular `uids and thereby protects
it from potentially toxic substances in the bloodstream, as well as en-
ables the cerebrospinal `uid of the brain to be precisely controlled [3].
Drug distribution into the cerebrospinal `uid (CSF) cannot be an indi-
cator of BBB transport. CSF is in rapid equilibrium with the blood by
convection, and the substances injected into the CSF diffuse quickly to
blood, and poorly to the brain. The BBB function is enhanced by the
high level of ef`ux transporters especially P-glycoprotein (P-gp). Strong
junctions of ions and small hydrophilic molecules to P-gp reduce perme-
ation of such solutes [4], closing any paracellular pathway [5]. Conse-
quently, the brain-to-blood ef`ux systems, plasma protein binding, en-
zymatic activity, and cerebral blood `ow can greatly alter the amount
of the substance crossing the BBB. Only unionized, lipophilic and low
molecular weight compounds can diffuse freely through the endothelial
membrane and may passively cross the BBB if they do not bind to the
ef`ux transporters located in the brain capillaries of endothelial cells.
Small ions and polar molecules cannot cross this barrier [6,7].
Many coumarins and their derivatives underwent extensive investi-
gations aimed to assess their bene_cial effects on human health [8 10].
It has been shown, that they impact the CNS based on dopaminer-
gic and serotonergic aanities, interactions with benzodiazepine re-
ceptors, and/or inhibition of cholinesterase and
monoamine oxidases [11]. Among different pharmacological properties,
their strong binding with the CNS receptors appears to be a very impor-
tant biochemical feature, and thus coumarins can be a valuable resource
of chemotherapeutics for the treatment of CNS diseases. Many scien-
ti_c groups search for the new antipsychotic drugs among coumarin de-
rivatives, based on their aanities to serotonergic receptors 5-HT⁠1A and
5-HT⁠2A [12 14]. It was found that activities of coumarin analogs can be
modulated via their molecular architecture. For example, it was shown
that the presence of bulky aliphatic chain like a sec-butyl group at C-8
position decreased the antipsychotic activity, but the substitution of the
methoxy group at C-3 position is favorable for their pharmacologic po-
tential [15]. It was also observed that compounds with the N-arylpiper-
azine fragment and the methyl groups at C-3 and/or C-4 positions of the
coumarin ring were the most promising ones in various biological tests
[13].
Human serum albumin (HSA), one of the main carrier proteins plays
an important role in the transport and disposition of exogenous and en-
dogenous compounds present in the blood [16]. It is known that dis-
tribution in the body and pharmacological effect of chemotherapeutics
are both correlated with the nature and magnitude of drug-HSA in-
teractions. Although bound and unbound drug concentrations are pre-
dominantly in equilibrium, problems might occur if the HSA aan-
ity of a drug is extremely high. Weak plasma protein binding leads
to a short lifetime and/or poor tissue distribution of the drug and
other organic compounds, whereas strong binding decreases the con-
centrations of free drugs in plasma [17]. The spe
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Table 1
Theoretical values of topological polar surface area (TPSA), percentage of unbound drug to blood plasma proteins (%Unbnd), blood-to-plasma concentration ratio (RBP), BBB _lter,
blood-brain barrier partition coef_cient (logBB), likelihood of the P-glycoprotein inhibition (P-gp) and predicted proton dissociation constants (pK⁠a) for coumarins 1a 4a and 1b 4b.
Compound TPSA %Unbnd RBP BBB _lter logBB⁠a P-gp pK⁠a
Expected values
( 90Å⁠2) (>10%) (<1) (High/low)
62.99 1.771 0.655 High 0.183 I 6.98
72.22 1.937 0.627 High 0.190 I 6.74
86.78 2.301 0.608 High 0.610 I 6.93
62.99 0.865 0.667 High 0.257 I 6.99
62.99 2.065 0.648 High 0.282 I 7.39
72.22 2.099 0.622 High 0.096 I 7.20
86.78 2.347 0.604 High 0.543 I 7.14
62.99 0.997 0.660 High 0.368 I 7.41
a According to the classi_cation made by Ma et al. [57]: high absorption to CNS: logBB more than 0.3; middle absorption to CNS: logBB 0.3 ( 1.0); low absorption to CNS: logBB less
than 1.0.
Table 2
Prediction of interactions with various isoforms of hepatic microsomal cytochromes
CYP450 enzymes for coumarins 1a 4a and 1b 4b.
Compound CYP
Mode of action
1A2 2C9 2C19 2D6 3A4
S I S I/S I/S
S I S I/S I/S
S I S I I/S
S I S I/S I/S
S I S I/S I/S
S I S I/S I/S
S I S I I/S
S I S I/S I/S
I denotes inhibition of CYP isoforms; S denotes substrate for CYP isoform.
ci_c physiological activity of the aromatic and heterocyclic ligands upon
adduct formation with serum albumin originates from the presence of
two hydrophobic pockets in subdomains IIA (Sudlow site 1) and IIIA
(Sudlow site 2) of HSA [18]. HSA contains a single intrinsic trypto-
phan residue at position 214 in domain IIA, where a large hydrophobic
cavity is present, and its `uorescence is sensitive to the ligands bound
nearby [19]. Therefore, information about the HSA-ligand binding can
be obtained by the measurement of intrinsic `uorescence intensity of
the tryptophan residue before and after the addition of the tested com-
pounds. HSA is a well-known transport peptide of numerous coumarin
derivatives, especially for warfarin an anticoagulant drug [20 23]. It
has been reported that compounds with coumarin, chromone and chro-
manol rings can bind to HSA in subdomain IIA. Elimination of the 4-hy-
droxy group decreased the binding aanity in this series of compounds,
and pyranone in not a ligand to HSA [24]. It was also shown that the
acetyl group at C-8 position significantly decreased HSA binding but
its role in the ligand-protein interactions was not explained definitely
[25]. Therefore, additional information concerning the structural fea-
tures which favor HSA binding for very potent substances evaluated in
vitro assays is of high demand in the course of drug search. The analy-
sis of potential drug binding to plasma protein is interesting because the
unbound drug fraction affects many pharmacokinetic parameters as the
steady-state distribution volume, but also it provides useful information
for the design prediction of the administration regimen dose.
In the present study, we selected eight compounds (1a 4a, 1b 4b)
synthesized in our research group which belongs to the 8-acetyl-7-hy-
droxy-4-methylcoumarin family connected with the N-arylpiperazine
substituent via propyloxy or butyloxy linkers (Fig. 1). These coumarin
derivatives showed very high aanities to 5-HT⁠1A by in vitro assays
(IC⁠50 within range 0.8 2.2nM) and high aanities to 5-HT⁠2A (8 138nM)
receptors [26], which are the initial factors in the
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Table 3
Predicted toxicity parameters for coumarins 1a 4a and 1b 4b: maximum recommended therapeutic dose MRTD, level of alkaline phosphatase (AlkPhos); level of -glutamyl transferase
(GGT), level of serum glutamate oxaloacetate transaminase (SGOT), level of serum glutamate pyruvate transaminase (SGPT), level of lactate dehydrogenase (LDH).
Compound MRDT AlkPhos GGT LDH SGOT SGPT
Expected values
(>3.16mg/kg/day)
Below 3.16 NT NT NT NT NT
Above 3.16 NT NT NT NT NT
Below 3.16 NT NT NT NT NT
Above 3.16 NT NT NT NT NT
Below 3.16 NT NT NT NT NT
Above 3.16 NT NT NT NT NT
Below 3.16 NT NT NT NT NT
Above 3.16 NT NT NT NT NT
Table 4
Proton dissociation constants (pK⁠a) for coumarins 1a 4a and 1b 4b estimated from the pH-dependence of n-octanol/water distribution coef_cient (D⁠pH) values; distribution of the ligand
species at pH 7.40 in water; partition coef_cients (P) of the ligand species L and HL⁠+ and distribution coef_cient (D⁠7.4) at pH 7.40 in n-octanol/water; absorption maximum ( ⁠max) and
molar absorbance ( ) of the HL⁠+ form; (EM)⁠max and relative `uorescence emission intensity values for the compounds at pH 7.4; conditional binding constants to HSA on site 1 (log K⁠Q)
(t=25°C, I=0.10M KCl).
1a 2a 3a 4a 1b 2b 3b 4b
pK⁠a UV vis 6.95±0.04 6.86±0.03⁠a 6.90±0.04 6.35±0.08 7.20±0.05 7.13±0.04 7.15±0.04 6.72⁠b
HL⁠+⁠7.40 (%) 26 22 24 8 39 35 36 17⁠b
L⁠7.40 (%) 74 78 76 92 61 65 64 83⁠b
log P⁠L 3.26±0.01 2.95±0.01 3.14±0.02 3.5±0.1 3.41±0.03 3.08±0.04 3.27±0.05 3.65⁠b
log P⁠HL+ 0.84±0.08 0.84±0.06 0.61±0.09 1.96±0.06 0.97±0.08 0.90±0.04 0.80±0.08
log D⁠7.40 3.11 2.80 2.99 3.35 3.26 2.93 3.12 3.52⁠b
⁠max/nm ( /M⁠ 1 cm⁠ 1) of HL⁠+ 321(12400) 321(14100) 321(15500) 321(11600) 322(14100) 322(17100) 322(16700) 322(13900)
(EM)⁠max (nm) 422 424 405 424 423 424 397 408
Relative intensity⁠c 0.29 0.31 0.64 0.29 0.41 0.46 1.00 0.54
log K⁠Q (HSA)⁠d 5.25±0.1 5.33±0.1 5.75±0.1 5.96±0.1 n.d n.d. 5.70±0.1 5.88±0.1
K⁠D⁠e 5.6 M 4.7 M 1.8 M 1.1 M 2.0 M 1.3 M
a pK⁠a =7.06±0.01 determined by UV vis spectrophotometric titrations.
b Predicted value based on the tendencies of the other derivatives.
c Relative `uorescence intensities measured at emission maxima and at (EX)=322nm at pH 7.4.
d Measured at pH 7.4 (20mM phosphate buber, 0.1M KCl).
e K⁠D =dissociation constant of the HSA adduct (K⁠D =1/K⁠Q).
selection of compounds to the next step in the pipeline of drug discov-
ery to target CNS. Before in vivo tests, the most favorable strategy is to
calculate the most important drug likeness parameters, with special em-
phasis on the requirements of the CNS drugs. As a result, we evaluated
ADME parameters based on the chemical structures for our set of de-
rivatives to estimate their propensities cross BBB, as well as evaluating
their toxicities. The interaction between coumarin derivatives and HSA
was measured during blood transportation process in vitro under physi-
ological conditions by `uorescence spectroscopy and was simulated by
molecular docking and molecular dynamics (MD) methodology. We be-
lieve that this study provides basic data for clarifying the in vivo binding
mechanisms of coumarin derivatives with human serum albumin.
2. Materials and methods
2.1. Theoretical methodology
2.1.1. Chemical structures of tested coumarins and HSA
Eight compounds were selected and studied (Fig. 1): 1a
(8-acetyl-7-{3-[4-(2-`uorophenyl)piper-
azin-1-yl]propoxy}-4-methylchromen-2-one), 2a
(8-acetyl-7-{3-[4-(3-methoxyphenyl)piper-
azin-1-yl]propoxy}-4-methylchromen-2-one), 3a
(8-acetyl-7-{3-[4-(2-cyanophenyl)piper-
azin-1-yl]propoxy}-4-methylchromen-2-one), 4a
(8-acetyl-7-{3-[4-(2,3-dichlorophenyl)piperazin-1-yl]propoxy}-4-
4
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Fig. 2. pH-Dependent UV vis spectra of 2a and at the upper side calculated individual
molar spectra of the ligand species in the two protonation states L and HL⁠+. (c=19.6µM;
l=2cm; t=25°C; I=0.10M (KCl)).
Fig. 3. Measured ( ) and _tted distribution coef_cients (D⁠pH) for 2a at different pH val-
ues. Fitted curves correspond to the model 1 where only the distribution of the neutral
form is expected (dashed line), and to the model 2 where both L and HL⁠+ forms may dis-
tribute between the polar and non-polar phases (solid line). Inset shows the initial part of
the functions in the pH range from 2.0 to 6.0. (D⁠pH values were determined in n-octanol/
water system at the indicated pH values by traditional shake `ask method; see details in
the Section 2.2.2).
Fig. 4. Fluorescence emission spectra of HSA 4a system. The grey dotted line shows
the spectrum for 4a alone at 10µM concentration. (c⁠HSA =1 M; c⁠comp =0 10 M;
⁠EX =295nm; t=25°C; pH=7.40 (20mM phosphate buber); I=0.1M (KCl)).
methylchromen-2-one), 1b (8-acetyl-7-{4-[4-(2-`uorophenyl)piper-
azin-1-yl]butoxy}-4-methylchromen-2-one), 2b
(8-acetyl-7-{4-[4-(3-methoxyphenyl)piperazin-1-yl]bu-
toxy}-4-methylchromen-2-one), 3b
(8-acetyl-7-{4-[4-(2-cyanophenyl)piperazin-1-yl]bu-
toxy}-4-methylchromen-2-one), and 4b
(8-acetyl-7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]bu-
toxy}-4-methylchromen-2-one).
Fig. 5. Measured quenching of the Trp `uorescence emission intensity of HSA as I/I⁠0 (%)
by the addition of the propyloxy derivatives (a): 1a ( ), 2a ( ); 3a ( ); 4a ( ), and
butyloxy derivatives (b): 1b ( ), 2b ( ); 3b ( ); 4b ( ). Empty symbols correspond to
the relative emission of the compounds alone. (c⁠HSA =1 M; ⁠EX =295nm; ⁠EM =340nm;
t=25°C; pH=7.40 (20mM phosphate buber); I=0.10M (KCl)).
They belong to two groups of coumarin derivatives, which differ in the
length of the linker between two rings: the coumarin and the piperi-
dine. Namely, compounds 1a 4a are composed with propylene but com-
pounds 1b 4b with a butylene linker. Coumarin derivatives are poorly
soluble in water so prior biological tests they were transformed into hy-
drochlorides to increase their solubility. In each case, the cations were
used in the theoretical studies, and the site of protonation was pro-
posed. The starting structures of the coumarin derivatives were con-
structed by Discovery Studio 2017R2 visual interface BIOVIA [27]. The
geometries of all compounds were optimized using the density func-
tional theory (DFT) with the B3LYP/6-311G (d,p) hybrid functional as
implemented in Gaussian 09 [28]. The known crystal structure of HSA
(PDB ID: 2BXD), which included a warfarin ligand in active site was ob-
tained from the RCSB Protein Data Bank. Ligand, water molecules, and
inorganic ions were removed, hydrogen atoms were added, and the cal-
culations were made at the physiological pH.
2.1.2. Prediction of ADMET descriptors
ADMET parameters were computed by applying ADMET Predictor⁠TM
version 8.5 program [29] using qualitative and quantitative models.
Various drug likeness parameters like Lipinski s rule of _ve, the topo-
logical polar surface area (TPSA), the proton dissociation constants
(pK⁠a), a Maximum Recommended Therapeutic Dose (MRTD), qualita-
tive likelihood of penetrating the blood-brain barrier (BBB__lter) ex-
press as high/low, the logarithm of the blood-brain barrier partition
coef_cient logC⁠brain/C⁠blood (logBB), percentage of unbound drug to pro-
teins within blood plasma (%Unbnd), blood-to-
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Fig. 6. Three-dimensional `uorescence spectra of HSA (a) compound 3a (b) and HSA 3a (1:11) system (c); peak intensities and wavelength coordinates (Intensity, [ ⁠EX, ⁠EM expressed
in nm]) are indicated in the _gure (c⁠HSA =1 M; c⁠comp =11 M; t=25°C; pH=7.40 (20mM phosphate buber); I=0.10M (KCl)).
Fig. 7. Emission spectra of 3a upon addition of HSA. Inset shows the intensity changes
at ⁠EM =410nm. (c⁠comp =2.8 M; c⁠HSA =0 23 M; ⁠EX =330nm; t=25°C; pH=7.40
(20mM phosphate buber); I=0.10M (KCl)). Spectra are corrected by the light scattering
effect of HSA, see details in the Supplementary Materials, Fig S6.
plasma concentration ratio (RBP=C⁠whole-blood/C⁠plasma) and likelihood of
the P-glycoprotein (P-gp) inhibition were estimated for all compounds
at pH 7.4. Prediction of metabolic phase I indicators was made us-
ing cytochrome P450 (CYP 450) forms CYP 1A2, 2C9, 2C19, 2D6 and
3A4. All the CYP-metabolites generated for each compound were eval-
uated for risk potential whenever it was possible. Phase II metabolism
of coumarin derivatives was investigated to determine the probability
whether human uridine 5 -diphosphate-glucuronosyltransferases (UGT)
can be involved. Hepatotoxicity parameters were specifically studied
using relevant biomarkers: alkaline phosphatase (AlkPhos), serum glu-
tamate oxaloacetate transaminase (SGOT/AST), serum glutamate pyru-
vate transaminase (SGPT/ALT), -glutamyl transferase (GGT) and lac-
tate dehydrogenase (LDH).
2.1.3. Starting structures of ligands by molecular docking simulations
The molecular docking experiments were carried out using the
Lamarckian Genetic Algorithm (LGA) implemented in the AutoDock
4.2.3 program [30]. HSA was held rigid, all torsion bonds of the lig-
ands were considered as free, and there was no consideration regard-
ing the effect of solvent on the interactions. The protein input _les were
prepared for docking by adding Gasteiger charges on atoms. Based on
the site-speci_c markers used in our experiment, the coumarins were
docked to the Sudlow site 1. The size of the grid box was de_ned in
the shape of a three-dimensional grid (50×50×50Å) at a resolution
of 0.375Å. The docking parameters used were as follows: GA popula-
tion size: 150 and the maximum number of energy evaluations: 250 000.
During docking, a maximum number of top 30 conformers was consid-
ered, and the root means square (RMS) cluster tolerance was set to 2Å.
The conformers corresponding to the lowest free energy were used as
the starting points in the MD simulations.
2.1.4. HSA-ligand complexes by molecular dynamics simulations
MD simulations of the ligand-HSA complexes were performed in
solution to better re`ect experimental systems and the intermolecular
interactions which play a crucial role in their stability. We used the
CHARMm force _eld [31] implemented in the module of Discovery Stu-
dio 2017R2. Each protein-ligand complex was immersed in a cubic box
of TIP3P water molecules [32] (12Å from the solute surface) and neu-
tralized by the addition of chloride anions. The MD strategy consisted
of two-step energy minimization of the solvated complexes. First of all,
the water molecules were optimized using the steepest descent method
with 1000 steps, and then the conjugate gradient method was employed
for another 1000 steps while protein and ligand were kept frozen. The
restraints were weak with force constant of 10kcalmol⁠ 1 Å⁠ 2. Secondly,
using the same approach in the _rst step above was performed with all
atoms relaxed. The MD protocol contained a heating step performed for
50ps up to 300K. Before proceeding to production, MD step equilibra-
tion was done at 300K for 50ps. In the stages of heating and equilibra-
tion, the solutes (protein and ligand) were _xed with force constant of
2kcalmol⁠ 1 Å⁠ 2. The equilibrated system was taken as the starting struc-
ture for production runs using two phases. In the _rst phase, NVT was
performed at 300K for 200ps in the presence of a weak harmonic re-
straint on the solute, and in the second phase NPT at 300K and 1bar for
5ns. The periodic boundary conditions were used and the motion equa-
tions were integrated by applying the Leapfrog Verlet algorithm [33]
with a time step of 2 fs. The trajectories were recorded at 10ps interval.
2.1.5. Binding free enthalpy calculations using MM-PBSA
The free enthalpy calculations were carried out using the MM-PBSA
approach [34] embedded in Discovery Studio 2017R2. The atomic coor-
dinates of HSA and each ligand were extracted from a single trajectory
of the MD simulations obtained using explicit water molecules. Each
binding free enthalpy was calculated based on the average structures
obtained from the last 2ns of MD trajectories. The components of each
complex were minimized using the conjugate gradient method for 10
000 steps after 100 steps of the steepest descents algorithm and a dielec-
tric constant of 4 for the electrostatic interactions until the RMS gradi-
ent of the structure was less than 0.001kcalmol⁠ 1 Å⁠ 1. The binding free
enthalpy ( G⁠bind) between a ligand and a protein was estimated given
the functional form of MM-PBSA formalism in Eq. (1).
(1)
where G⁠HSA-ligand is free enthalpy of complex, G⁠HSA is free enthalpy of
HSA and G⁠ligand is free enthalpy coumarin derivative.
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Fig. 8. View of coumarin derivatives in site 1 of HSA. (a) Structure of HSA showing the subdomains and binding sites of compounds 1a 4a and 1b 4b. Compounds around the binding
pocket are shown as spheres. (b) The hydrophobic and hydrophilic amino acid residues surrounding the ligands. Surface hydrophobicity was depicted by the shaded colors: brown the
hydrophobic and blue lipophilic regions. (c) Superposition of compounds: 1a (green), 2a (blue), 3a (orange), 4a (red), 1b (dark green), 2b (dark blue), 3b (yellow) and 4b (pink). (For
interpretation of the references to colour in this _gure legend, the reader is referred to the web version of this article.)
2.2. Experimental methodology
The lipophilicities and the dissociation constants for coumarin de-
rivatives together with equilibrium constants for HSA-ligand complexes
were determined experimentally.
2.2.1. Preparation of stock solutions of HSA and coumarins
HSA (with fatty acids as lyophilized powder), KOH, HCl, KCl and
all buber components used for lipophilicity measurements are
Sigma-Aldrich products in puriss quality. Milli-Q ultrapure water was
used as a solvent of the samples and stock solutions. HSA solution was
prepared in phosphate buber (20mM, pH 7.40) containing 0.1M KCl
strictly on the same day as the experiment was done. Estimated con-
centration of HSA stock solutions was calculated from its UV absorp-
tion: ⁠280 nm(HSA)=36850M⁠ 1 cm⁠ 1 [35]. Hydrochloride salts of the
coumarin derivatives were dissolved in slightly acidic water (pH 4) at
100µM concentration.
2.2.2. Estimation of pH-dependent lipophilicity and proton dissociation
constants (pK⁠a) for coumarins
Distribution coef_cient (D⁠pH) values of the compounds were deter-
mined by the traditional shake-`ask method in n-octanol/bubered aque-
ous solution at various pH values at 25.0±0.2 °C. pH values of the sam-
ples were adjusted with n-octanol pre-saturated aqueous solutions con-
taining different buber systems at ca. 50mM concentration and 0.10M
KCl. Applied pH values are follows: pH=2.01 (H⁠3PO⁠4/NaH⁠2PO⁠4);
pH=3.01 (formic acid/Na-formate); pH 4.01 (formic acid/Na-formate);
pH 5.01 (acetic acid/Na-acetate); pH 5.41 (2-(N-morpholino)ethane-
sulfonic acid (MES)/its Na-salt); pH 6.03 (MES/its Na-salt); pH 6.53
(MES/its Na-salt); pH 7.04 (NaH⁠2PO⁠4/Na⁠2HPO⁠4); pH 7.50
(NaH⁠2PO⁠4/Na⁠2HPO⁠4); pH 8.45 (NH⁠4Cl/NH⁠3); pH 8.97 (NH⁠4Cl/NH⁠3);
pH 10.30 (3-(cyclohexylamino)-1-propanesulfonic acid (CAPS)/its Na
salt). Compounds were dissolved in slightly acidic n-octanol pre-sat-
urated water (pH 4, I=0.10M KCl) and aliquots were mixed with
the certain buber systems in 1:2vol ratio in order to get the stock
solutions. Final com
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Table 5
Theoretical and experimental free enthalpy of binding to HSA, and average distance of lig-
and to tryptophan Trp-214 for coumarin derivatives.
Compound G⁠bind (kcal/mol) G⁠exp⁠a (kcal/mol) r (Å)
7.69 7.15 8.94
7.84 7.26 8.18
8.64 7.84 7.61
9.66 8.12 7.06
6.36 13.89
7.75 10.13
8.45 7.77 8.94
-8.89 8.01 7.59
a G⁠exp =-2.303 RT log K⁠Q
pound concentration was 5 40µM, and exact pH values were measured
with an Orion 710A pH-meter equipped with a Metrohm combined elec-
trode (type 6.0234.100) after three-point calibration of the electrode
system. Stock solutions and water presaturated n-octanol were gently
mixed in 1:1, 1:0.02 or 1:0.01vol ratio with Heidolph Reax 2 overhead
shaker ( 20 revolutions per minute (rpm)) for 2h. The mixtures were
centrifuged with Eppendorf MiniSpin Plus centrifuge (5000rpm, 3min).
After phase separation, UV visible (UV vis) spectrum of the compound
in the aqueous phase was compared to that of the original stock solu-
tions and D⁠pH values of the compounds were calculated according to the
following equation (Eq. (2)):
(2)
A Thermo Scienti_c Evolution spectrophotometer and a Hewlett
Packard 8452A diode array spectrophotometer were used to measure
the UV vis spectra in the interval 200 500nm.
pH dependence of the D⁠pH values were utilized to estimate pro-
ton dissociation constants (pK⁠a) of 1a 4a and 1b 4b. According to our
model both protonated (HL⁠+) and charge neutral (L) species distribute
between the polar and non-polar solvent phases, namely both P⁠HL⁠+ and
P⁠L constants can be derived from the measurements since D⁠pH value is
equal to the corresponding partition coef_cient (P) value in that pH
range where the compound is presented practically in one single proto-
nation state (either HL⁠+ or L). The pK⁠a values were calculated according
to Eq. (3):
(3)
where [H⁠+] is the free proton concentration in aqueous phase cal-
culated from the measured pH. The pK⁠a values were _tted with the
computer program PSEQUAD [36] using the pH D⁠pH data pairs and
P⁠HL⁠+, P⁠L constants. A more detailed description of lipophilicity models
and model selection can be found in the Supplementary Materials.
2.2.3. Spectro?uorometric measurements of interaction with HSA
Phosphate buber (20mM, pH 7.4) with 0.10M KCl was used for
sample preparation; spectra were recorded after 10min incubation. Two
kinds of experiments were carried out: 1µM HSA and various amounts
of coumarin compound (from 0 to 25eq.) were used for quenching ex-
periments; and intrinsic `uorescence of the compounds was examined in
samples containing 2.4 3.3 M compound and 0 23 M HSA. The exci-
tation wavelength was chosen for 295nm in quenching experiments; the
emission intensities were read in the range of 310 500nm with 5nm/
5 nm slit widths. In the second experiment, compounds were excited
at 330nm; the emission was recorded in the range of 340 550nm with
slit widths of 10nm/10nm. Spectra were corrected by the light scatter-
ing effect of HSA appearing at these conditions. Computer program PSE-
QUAD was utilized for calculation of equilibrium constants for HSA lig-
and complexes from both types of experiments as described in our for-
mer work [37].
Three-dimensional `uorescence spectra were obtained between 230
and 400nm excitation and 250 550nm emission wavelengths with slit
widths of 5nm/5 nm. Corrections for self-absorbance and inner _lter ef-
fect were necessary since the exciting and emitted light were partly ab-
sorbed by the compounds. The following formula (Eq. (4)) was used for
spectral correction:
(4)
where corrected `uorescence (F⁠corrected) is given as the product of the
measured intensity (F⁠measured) and 10 to the power of average ab-
sorbances measured at the excitation (A⁠(⁠EX⁠)) and emission wavelengths
(A⁠(⁠EM⁠)).
3. Results and discussion
3.1. Assessing of ADMET parameters
3.1.1. Blood-brain barrier in silico assay
The physico-chemical parameters with relation to Lipinskís rule of
_ve are presented in the Supplementary Material, Table S1 for 1a 4a
and 1b 4b. As can be seen the tested coumarins ful_ll the majority of
basic requirements for orally administrated drugs. Only the values of
molecular weight (MWt) and log D are fairly high for 4b with the two
chlorine substituents. Since these parameters should be in speci_c range
for substances aimed at the CNS their values were scrutinized below to-
gether with the following parameters being crucial for evaluation of BBB
penetration which are shown in Table 1. The topological polar surface
area (TPSA) is a key parameter for prediction of CNS penetration. TPSA
was suggested to be a measure of a molecule s hydrogen bonding and its
value should not exceed certain limit lower than for other drug s classes
[38,39]. Two limits were proposed, namely a lower limit of 60 70Å⁠2
and a higher limit of 90Å⁠2 [40 42]. TPSA values of all compounds
in our study are in these ranges which creates basic conditions for
the penetration BBB. MWt is an important parameter determining the
lipid-mediated free diffusion of molecules across the BBB. Small mole-
cules may cross the BBB due to their MWt lower than 400 500gmol⁠ 1,
however, according to the suggestion of van de Waterbeemd et al. [43],
MWt should be below 450gmol⁠ 1 or even below 400gmol⁠ 1 [44], be-
cause the BBB is a specialized structure between the cerebral capillar-
ies and the brain parenchyma. Only 1a and 3a, reported herein, have
MWts 450, but 2a, 1b and 3b show values close to 450gmol⁠ 1. Nev-
ertheless, larger molecules can be transported by receptor- or trans
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Fig. 9. Structures of the 1a HSA, 2a HSA, 3a HSA and 4a HSA complexes, and 2D view of all HSA residues interacting with the ligands resulting from MD simulations (residues
involved in hydrogen bonding marked as green and cyan circles; in hydrophobic interactions marked as pink circle and electrostatic interactions marked as orange circle). (For interpreta-
tion of the references to colour in this _gure legend, the reader is referred to the web version of this article.)
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Fig. 10. Structures of the 1b HSA, 2b HSA, 3b HSA and 4b HSA complexes, and 2D view of all HSA residues interacting with the ligands resulting from MD simulations (residues
involved in hydrogen bonding marked as green and cyan circles; in hydrophobic interactions marked as pink circle and electrostatic interactions marked as orange circle). (For interpreta-
tion of the references to colour in this _gure legend, the reader is referred to the web version of this article.)
porter-mediated systems. Another important drug property that governs
permeation across the CNS tissue barrier is the molecular lipophilic-
ity, expressed as log P, where P is the partition coef_cient.
Capillaries of the brain are devoid of aqueous pores which facilitate
aqueous diffusion, thus lipid diffusion becomes a critical determinant
of BBB drug penetration, and a higher lipophilicity is required to
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achieve greater CNS ef_cacy. On the other hand, the more lipophilic
compounds frequently demonstrate a higher level of binding to serum
proteins. From the other side, the lowest log P values of 2 were sug-
gested to be the most optimal to minimize the metabolism and toxic
side effects. Thus, lipophilicity and protein binding can be considered as
con`icting characteristics in regard to CNS penetration. The BBB pen-
etration was optimal for several classes of CNS active substances when
log P values were in the range of 2 5 [45,46]. The log P values for
tested coumarins were in the range 3.41 4.98 close to that of marketed
CNS drugs. The logarithm of the distribution coef_cient (log D), which
characterized ionic substances, needs to be>0 and less than 4 for better
brain permeation [43]. For eight analyzed coumarins log D values are
lower than log P values and fall within the range 3.32 4.68. Only deriv-
atives 4a and 4b with two Cl substituents show relatively high log D val-
ues, which indicates a higher probability of binding to plasma proteins.
An important parameter is hydrogen bonding that occurs with the sur-
rounding medium i.e. water. It has been reported that for a compound
to be transported through the BBB, the H-bond donors should be 3 and
H-bond acceptors should be 7 [47]. An inspection of the investigated
coumarins H-bond donors and acceptors suggests that all have a poten-
tial to effectively cross the BBB. A speci_c attention was given to the
proton dissociation constant (pK⁠a). Fischer et al. [48], estimated pK⁠a
limit between 4 and 10 in a study of comparative properties for BBB
penetration. The predicted pK⁠a values of all compounds fall in the range
of 6.74 7.41 (Table 1) and the shortening the linker from the butylene
to the propylene chain decreases the pK⁠a values. The computed values
are in good agreement with the experimental values (see Section 3.2).
On the basis of our _ndings, the calculated BBB permeation para-
meters as BBB__lter and blood-brain barrier partition coef_cient logBB
are promising for tested coumarins (Table 1). BBB__lter is a qualitative
likelihood of crossing the BBB and logBB is a measure of the partition-
ing between brain and blood tissue, quanti_ed by the ratio of the solute
concentrations in brain and blood. The BBB__lter parameter is indicated
as high, and the values of logBB s are found in the range from 0.610
to 0.368, that correlates with the permeation of high-to-moderate for all
tested compounds. The logBB values for three compounds 1b, 4a and
4b, with halogen atoms were found to be close to 0.3 values, suggest-
ing that this kind of substitution increases the potential of drugs for BBB
penetration. Compounds 3a and 3b with cyano group have the lowest
logBB values (close to 0.6) suggesting an unfavorable impact of cyano
group on BBB crossing.
Yet another important property of a potential drug is its ability to
bind to plasma proteins (HSA and ⁠1-acid glycoprotein (AGP)), which
is in most cases considered as undesirable. Depending on the drug and
the target, high aanity to plasma proteins may consequently increase
or decrease the ef_cacy of drug transport. A drug bound weaker can
more ef_ciently traverse cell membranes or diffuse. The active ef`ux
transporter at the BBB is P-glycoprotein (P-gp), which performs ac-
tive back-transport of drugs from the brain to blood. A successful CNS
drug should not be an ef_cient P-gp substrate (in vivo) and also possess
low-aanity to serum albumin (K⁠D <10 M) [49]. Three theoretical pa-
rameters characterize these properties: the percent of drug unbound to
protein within blood plasma %Unbnd, the concentration of the drug in
whole blood compared to plasma RBP, and the mode of the interaction
with P-gp. For the analyzed coumarins the values of %Unbnd are in the
region 0.997 2.347%, and the values of RBP in the region 0.604 0.667
(Table 1), what suggests that all compounds fall in the region of strong
plasma protein binding.
Emerging evidence has highlighted a potential role for the ef`ux
transporter P-gp expressed at the BBB in the etiology of treatment-re
sistant depression [50,51]. This neurological disorder can be improved
by inhibiting drug ef`ux at the blood brain barrier. In our study, 1a 4a
and 1b 4b exert P-gp inhibition effects (Table 1) what suggests that
those coumarins can suppress P-gp activity and can be considered as
promising compounds for further development steps as novel therapeu-
tic agents.
3.1.2. Biotransformation of the tested coumarins
The processes of drug biotransformation are the enzymatic conver-
sions of the drugs to their metabolites which are classi_ed as either
phase I or phase II reactions based on the nature of the chemical mod-
i_cations and the enzymes involved. The majority of phase I reactions
are mediated by a large family of CYP450 enzymes, while phase II
occurs predominantly by the UGT enzymes, distributed in various or-
gans in human body. Modes of action (inhibition/substrate) for differ-
ent isoforms CYP450 are presented in Table 2. All studied coumarins
are possible substrates for isoenzymes CYP1A2 and CYP2C19 and, on
the other hand, are likely to inhibit CYP2C9. Compounds (3a and
3b) with (2-cyanophenyl) piperazinyl moiety cannot be metabolized by
CYP2D6 isoform, while the other tested coumarins may be substrates
and inhibitors to both CYP2D6 and CYP3A4. Hypothetical metabolites
of tested coumarins are presented in Fig. S1 in Supplementary Materials.
We can see those main metabolites are aldehydes (up to 64%) which are
formed by breaking the C N bond at the piperazine ring. The remain-
ing metabolites are formed by hydroxylation of the benzene ring or the
methyl group at C-4 atom in coumarin ring moiety. Additionally, nine
main microsomal hepatic UGTs were examined to identify which iso-
forms may be responsible for coumarins glucuronidation reaction lead-
ing to their easier elimination. All coumarins are predicted to be sub-
strate for only one isoenzyme 1A4, whereas none of them was predicted
to be substrate for isoenzymes 1A1, 1A3, 1A6, 1A8, 1A9, 1A10, 2B7 and
2B15 (see Table S2 in Supplementary Materials).
3.1.3. Prediction of toxic e@ects
The predicted values of toxicity parameter for coumarins 1a 4a and
1b 4b are shown in Table 3. Among these toxicity parameters, MRTD
represents a qualitative assessment of maximum recommended thera-
peutic dose administrated orally. To develop an effective oral drug, the
MRTD value should be greater than 3.16 (mg/kg-bw/day), which can
indicate that the selected compound has fewer side effects. Compounds
2a, 2b, 4a, and 4b have MRTD value great than 3.16, indicating that
the appearance of side effects is less likely for these compounds. Among
compounds with MRTD values below 3.16 (mg/kg-bw/day) are deriv-
atives with `uoro and cyano substituents. Further parameters are re-
lated to a liver toxicity. During a screening, all coumarin derivatives
being predicted as non-toxic taking into account relevant biomarkers
(AlkPhos, GGT, LDH, SGOT, and SGPT).
3.2. Proton dissociation equilibria and intrinsic ?uorescence of the tested
coumarins
All investigated compounds have a poor aqueous solubility, accord-
ingly UV vis spectrophotometry, that requires lower concentrations,
was used for _rst to monitor their proton dissociation processes at
highly diluted concentrations (2 20µM) in pure aqueous solution. Mo-
lar absorbance of the studied compounds at acidic conditions (pH=2.5)
ranges from =11600 to 17100M⁠ 1cm⁠ 1 with ⁠max =321 322nm (see
Table 4). However, these intense ligand bands were found to be fairly
insensitive to the (de)protonation of the molecules. Only compound
2a (see Fig. 2) shows the tendentious but weak spectral changes at
pH between 5.0 and 8.5, and a pK⁠a value of 7.06±0.01 could be
calculated for this process. The depro
11
UN
CO
RR
EC
TE
D
PR
OO
F
T. Żołek et al. Bioorganic Chemistry xxx (2018) xxx-xxx
tonation constant most probably belongs to one of the piperazine ni-
trogens, i.e. to the proton dissociation of the ⁠+NH CH⁠2 moiety. Since
chromophore groups (coumarin and phenyl) are situated relatively far
from this piperazine nitrogen, UV absorption spectra are nearly insensi-
tive to the (de)protonation processes.
In order to obtain information about the protonation equilibrium of
the other compounds as well, pH-dependent lipophilicity studies were
carried out. The strongly lipophilic nature of the studied compounds re-
quired modi_ed experimental conditions, namely the water-to-octanol
volume ratio was changed in favor of the water (see details in the
Section 2.2.2). Two models were considered for the calculations (see
details in the Supplementary Materials, Section S-2). Fig. 3 shows the
n-octanol/water distribution coef_cients (D⁠pH) of 2a determined at dif-
ferent pH values. D⁠pH values in Fig. 3 clearly reveal the distribution
of the HL⁠+ species between the n-octanol and the aqueous phase, since
D⁠pH values are larger than zero even at the lower pH range (when only
HL⁠+ species is present in the solution). Measured D⁠pH values show a sig-
moidal shape in dependence of the pH and the in`ection point of this
curve corresponds to the pK⁠a of compound 2a, which was _tted with
the computer program PSEQUAD using the pH D⁠pH data pairs. In con-
trasts to the most widely accepted model (model 1), where an only dis-
tribution of the neutral form is expected (dashed line in Fig. 3), our
method operates with the partition of both protonation states (model
2). Obtained pK⁠a, log P⁠L and log P⁠HL values are listed in Table 4. The
lipophilicity of tested coumarins is within the limits for the drugs tar-
geted CNS. The pK⁠a values determined in aqueous solution are in the
range of 6.35 7.20. It is clear that displacement of the propylene linker
between the piperazine and coumarin moieties to butylene linker ten-
dentiously increases the log P⁠L and pK⁠a values. This phenomenon helped
us to predict these constants for 4b (see Supplementary Materials, Sec-
tion S-3, Fig. S3), that was found to be fairly insoluble in water at
pH>6.5. Chloride substitution of the compounds undoubtedly results
in increased acidity due to its high electronegativity. Fluorine monosub-
stitution interestingly leads to a small increase in the pK⁠a values com-
pared to the methoxy derivatives, and nitrile substitution has only a mi-
nor effect on the acidity of the compound as well. Notably, the com-
puted pK⁠a values are in good agreement with the constants reported
in our former work for their structural analogues containing the same
4-(4-phenylpiperazin-1-yl)propyloxy or -butyloxy group but in a differ-
ent position on the coumarin ring. Furthermore, the experimental pK⁠a
values _t well to the predicted ones in the case of ligands 1a, 1b, 2a,
2b, 3a, and 3b, although they differ more significantly for the dichlo-
rine substituted 4a and 4b.
Species distribution was calculated at pH 7.4 based on the deter-
mined pK⁠a values (Table 4). All the studied coumarins are protonated
partly at this particular pH, but 61 92% are present in the neutral (L)
form. Distribution coef_cients (D⁠7.40) calculated for pH 7.4 re`ect the
highly lipophilic character of the predominant neutral forms, and even
HL⁠+ forms are still lipophilic according to the log P⁠HL values deter-
mined. The `uorescent activity of the compounds is expected as they
contain the coumarin moiety. Accordingly, their intrinsic `uorescence
was examined and the position of emission maxima ( ⁠(EM)max) are col-
lected in Table 4. We have found that all compounds are weakly `uores-
cent and the actual protonation state of the molecules has no consider-
able effect on it. The characteristic high emission of 3-methyl coumarins
is most probably quenched by the acetyl substitution at position 8 on
the coumarin ring [52]. The butoxy derivatives show somewhat higher
`uorescence compared to their propoxy counterparts, 3a and 3b are the
most emissive compounds.
3.3. Interaction with HSA: spectro?uorometric studies
The interaction of compounds 1a 4a and 1b 4b with human serum
albumin (HSA) was investigated by `uorescence spectroscopy via the in-
trinsic `uorescence of the protein and the compounds as well. HSA, as
the most abundant protein constituent of blood plasma, has outstand-
ing capacity to transport a wide variety of endogenous compounds (e.g.
fatty acids, bilirubin, steroids, and metal ions) and pharmaceutics. Its
concentration in blood plasma is ca. 630 M [53,54]. HSA comprises hy-
drophobic binding sites 1, 2 and 3 located in the hydrophobic pockets in
subdomains IIA, IIIA and IB respectively. The only tryptophan (Trp214)
residue in HSA is responsible for most of the intrinsic `uorescence of
the protein and it is located near to site 1. Trp214 can be selectively ex-
cited at =295nm and it shows strong `uorescence between 310 and
400nm (with a maximum at 340nm) that can be attenuated by a bind-
ing event at or close to Trp-214 owing to its susceptibility to changes in
its environment [53 55]. Thus, direct studies on the binding at the pri-
marily assumed binding pocket become possible.
The HSA compound interaction was revealed to be quite fast in
time-dependence measurements (completed within few seconds, see Fig.
S4 in Supplementary Materials), therefore 10min incubation time was
used to ensure the equilibrium state for the HSA binding experiments. A
correction equation was used to reduce to significant self-absorption and
inner _lter effect of the compounds. Representative emission spectra are
presented in Fig. 4 for the 4a HSA system and in the Supplementary
Materials, Fig S5 for the 1b HSA system. As the studied compounds
are `uorescent themselves, their intrinsic emission bands partly overlap
with that of HSA. This phenomenon did not hinder the determination
of quenching constant. The two calculation methods, namely when re-
stricted wavelength range (310 ca. 340nm) was used and the emission
originated from the ligand was eliminated or when all the three compo-
nents (HSA, HSA ligand and unbound ligand) were considered to be
`uorescent provided similar quenching constants (log K⁠Q) within a stan-
dard deviation of±0.1. The computer program PSEQUAD was utilized
to compute conditional stability constants (log K⁠Q) which collected in
Table 4.
It is noteworthy that normalized quenching curves plotted against
the ligand-to-HSA ratios shown in Fig. 5 do not tend to zero, this can be
explained by the partial quenching of Trp-214 `uorescence. This phe-
nomenon was taken into consideration in our calculations (see details in
our former work [23]). According to Fig. 5 and to the calculated log K⁠Q
values in Table 4 the studied compounds show the different capability
to quench the protein `uorescence. The emission intensity was practi-
cally unaltered in the case of 1b and 2b, consequently, no quenching
constant could be computed; while remarkable binding of their propy-
loxy analogs 1a and 2a were revealed at site 1 (subdomain IIA). The
log K⁠Q values indicate a clear trend of the binding strength of the com-
pounds at site 1 on HSA: 4a>4b>3a 3b >> 2a>1a. Notably, the
differences between the values obtained for 4a, 4b, 3a, and 3b is rel-
atively small. According to the `uorescence quenching measurements
most compounds (except 1b and 2b) bind in a great manner on site 1,
and all propoxy derivatives show a somewhat higher aanity towards
this site compared to their butoxy pairs. The determined binding con-
stants (log K⁠Q =5.3 6.0) are slightly higher on average compared to
those of their close related analogs (log K⁠Q =4.8 5.8) reported in our
former work [23], but significantly lower than that of some reduced
Schib base coumarin compounds examined formerly by some of us [56].
As described in the former Section, the studied coumarin com-
pounds are `uorescent themselves and the effect of albumin bind-
ing on their intrinsic `uorescence was also investigated. Three-dimen-
sional `uorescence spectra recorded for 3a and/or HSA (Fig. 6)
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clearly show that the peak of the compound is increased moderately
upon binding to the protein while the peak belonging to the HSA is
quenched. Fig. 7 shows the spectral and intensity changes of 3a in the
presence of increasing amount of HSA and an unequivocal increase in
the intensity and slight blue shift of ⁠(EM) can be seen. Similar behav-
ior was found for the compounds 4a, 4b, 1b, and 2b also, con_rming
the sensitivity of their intrinsic `uorescence to binding to HSA. How-
ever, the latter ones responded with a decrease in their intensity upon
binding to the protein (see Fig. S6 and S7 in Supplementary Materials).
Based on the changes of the emission intensity binding constants could
be also computed. Calculated log K=5.73±0.1 for the 3a HSA sys-
tem corresponds well to the value determined in the quenching experi-
ment (log K⁠Q =5.75±0.1), which strongly supports that Sudlow site 1
represents the only significant binding pocket for this compound. Note-
worthy log K=6.51±0.1 and 6.23±0.1 for 4a and 4b respectively
are considerably higher than those of obtained in the quenching stud-
ies (log K⁠Q =5.96±0.1 and 5.88±0.1). This _nding refers to the ex-
istence of other binding sites of these two compounds on HSA besides
site 1. Even 1b and 2b show moderate interaction with HSA (see Fig.
S7 in Supplementary Materials) that takes place most probably not at
site 1, since no Trp quenching could be detected for these ligands. Log
K=4.67±0.1 could be computed for 2b only.
3.4. Starting structures of the HSA – Coumarins complexes by molecular
docking
As mentioned previously, binding of ligands to HSA is extraor-
dinarily eminent for the distribution and elimination of the drug as
well as duration and intensity of its pharmacological or toxicologi-
cal action. Molecular docking was conducted within subdomain IIA
in Sudlow s site 1 formed by six helices (Fig. 8a) as the most proba-
bly pocket for 7-O-arylpiperazinyl-4-methylcoumarins. The most favor-
able eight conformations of 1a 4a and 1b 4b with the lowest dock-
ing energy were found in 30 independent runs. The inner wall of the
pocket of site 1 is formed by hydrophilic side chains (Glu-153, Ser-192,
Lys-195, Lys-199, Arg-222, Arg-257, Ala-261, Ser-287, Ala-291, and
Glu-292), and a hydrophobic region (formed by Phe-146, Phe-156,
Phe-157, Trp-214, Leu-219, Leu-238, His-242, Leu-260, Ile-264, Ile-290,
and Ala-291) (see Fig. 8b and 8c). As shown in Fig. 8c coumarins are
on the entrance of the site 1 of HSA and the molecular distance be-
tween the coumarin ring and the core of the benzene ring in Trp-214
residues is in the range from 7.06 to 13.89Å. The de_ned starting loca-
tions of tested coumarin derivatives in HSA pocket are similar. Molecu-
lar dynamics simulations were made to better simulate the interactions
of 1a 4a and 1b 4b with the rests of amino acids or water molecules
and to get binding free enthalpy of the hypothetical complexes.
3.5. Binding free enthalpy and interactions of tested coumarins with HSA
MD simulations were made for each HSA - ligand complex in Sud-
low site 1 as the pocket suggested for coumarin derivatives. The RMSD
values between the ligand starting and the resulted average structures
were low in all cases. The binding free enthalpy values for 1a 4a
and 1b 4b calculated using the MM-PBSA method are presented in
Table 5 together with the experimental values obtained using Gibbs
isotherm and log K⁠Q values ( G⁠exp = 2.303 RT log K⁠Q). The experi-
mental values were not obtained for compounds 1b and 2b (see Section
3.3), suggesting that these two compounds interact with HSA beside
the site 1. The computational and experimental values of the free en-
thalpy differences are in the range of 0.54 to 1.54kcal/mol. The re-
sulting differences may be due by two reasons: one that the X-ray
structure of the HSA from crystals even after MD
simulation differs from that of the experimental aqueous conditions, and
the second that the ligands do not interact effectively with the hypothet-
ical pocket. The calculated strength of interactions with HSA decrease
in the sequence: 4a>4b>3a>3b>2a>2b>1a>1b ( 9.66kcal/
mol> 8.89kcal/mol> 8.64kcal/mol> 8.45kcal/
mol> 7.84kcal/mol> 7.75kcal/mol> 7.69kcal/
mol> 6.36kcal/mol, respectively). The MD resulting orientations of
ligands are presented in Fig. 9 for compounds 1a 4a with the propylene
linker and in Fig. 10 for compounds 1b 4b with the butylene linker.
The coumarin rings of all tested compounds were similarly located
within the hydrophobic binding pocket of HSA mainly surrounded by
Leu-238, Leu-260, Ile-264, Ile-290, and Ala-291, whereas the acetyl
group at 8-position makes hydrogen bonds primarily with Lys-199, and
His-242, Arg-257, and Ser-287. The rest of the molecule elements (alkyl
chains, piperazine and benzene rings) were the deciding factors show-
casing the differences in binding modes with HSA. The propylene linker
adopts an extended conformation in the complexes of compounds 1a 4a
with benzene ring twisted only in compound 2a, while the butylene
linker adopts a folded conformation in the complexes of compounds
1b 4b.
From the experimental studies of HSA `uorescence quenching, it is
clear that majority of tested compounds (except 1b and 2b) are located
next to the Trp-214 amino residue and show distinct differences in their
binding ability. The MD simulation results showed that the location
within the cavity of compounds 1a, 2a and 3a is almost the same, and
molecules are predominantly surrounded by interior pocket residues
Glu-153, Ser-192, Lys-195, Lys-199, and Glu-292 creating electrostatic
interactions and hydrogen bonds. Compound 3a with the 2-cyanophenyl
substituent is highly solvated by water molecules present inside the
pocket of site 1, which can play an important role in binding of 3a to
HSA. The nearest distance of propoxy derivatives from Trp-214 residue
is 7.06Å for compound 4a (Table 5), so the MD studies showed the
probability of strong quenching caused by 4a (Fig. 5a). The interac-
tion between compound 4a and HSA is dominated by hydrophobic con-
tacts with Phe-149, Phe-156, Phe-157, Leu-238, Leu-260, Ile-290, and
Ala-291, but there are also a number of speci_c electrostatic interac-
tions and hydrogen bonds. Especially the carbonyl group of the acetyl
substituent at 8-position forms hydrogen bonds with Arg-257, Ala-261
and Ser-267.
The butoxy derivatives 1b 4b are located in site 1 in such a way that
the distances to Trp-214 residue are 13.89Å for compound 1b, 10.13Å
for compound 2b, 8.94Å for compound 3b and 7.59Å for compound 4b.
These calculated distances stand in good agreement with the quench-
ing ef_cacy (see Fig. 5) of the compounds. The long distance close to
14Å can be an answer for the practically unaltered `uorescence inten-
sity for 1b and 2b upon binding to HSA (see Fig. S5 in Supplementary
Materials). Compounds 1b, 2b and 4b are predicted to be accommo-
dated in the HSA pocket in folded conformations, what is energetically
unfavorable, and decreases the hydrophobic interactions with surround-
ing amino acids (Fig. 10). Compound 1b forms the hydrogen bonds with
Ser-192, Lys-199 and His-242 and creates electrostatic interaction with
Lys-195 of HSA. The conformation of 3b differs from conformations 1b,
2b and 4b - the aromatic rings are located in opposed directions in rela-
tion to butyloxy linkers, and favorably interactions can be formed. Com-
pound 3b creates electrostatic and hydrogen bond interactions with in-
terior pocket residues Glu-153, Glu-292, Lys-199 and Ala-291, and hy-
drophobic interactions with Ala-191.
4. Conclusions
To sum up, in this work we have evaluated eight
8-acetyl-7-O-arylpiperazinyl-4-methylcoumarin derivatives with strong
binding ability towards 5-HT⁠1A and 5-HT⁠2A receptors aimed at gath-
ering in
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formation about their potential application as orally administered an-
tipsychotic agents. Theoretical values of drug likeness parameters as
lipophilicity, topological polar surface area, and BBB permeation char-
acteristics are in the regions for CNS drug candidates. The most promis-
ing compounds 4a and 4b have two Cl atoms at benzene ring. All
compounds are partly protonated at pH 7.40, and their pK⁠a values are
in the range 6.35 7.20. Studied coumarins can be metabolized by cy-
tochrome P450 to aldehydes and hydroxy derivatives. Tested coumarins
are predicted as P-glycoprotein inhibitors what can increase their rate
of uptake by the BBB. Unfortunately, the tested 8-acetyl-7-O-arylpiper-
azinyl-4-methylcoumarin showed moderate-to-strong binding to human
serum albumin. This phenomenon was studied experimentally and in sil-
ico in great detail. A logarithm of their experimental binding constants
obtained from quenching measurements was in the range 5.25 5.96.
Sudlow s site 1 was proposed as the significant binding pocket inside
HSA for compounds 1a, 2a, 3a and 3b, while for compounds 1b and 2b
the existence of other binding site is postulated, and for compounds 4a
and 4b, the commitment of two binding sites of HSA. Theoretical analy-
sis of complexes in Sudlow site 1 showed that hydrophobic interaction
is less probably for compounds 1b and 2b, and their distance to Trp-214
is much longer than for other compounds. Theoretical and experimen-
tal results suggest that longer aliphatic linker between coumarin and
piperazine moieties favored binding to HSA in other than Sudlow site 1
pocket. Overall the 8-acetyl-7-O-arylpiperazinyl-4-methylcoumarin de-
rivatives represent valuable lead compounds to be further studied in dif-
ferent preclinical assays as a possible treatment of diverse CNS diseases.
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